On October 19, 2026 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported presentations related to its clinical development programs at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23–27 in Madrid, Spain. The Company also highlighted the publication of an independent, investigator-led analysis of percutaneous hepatic perfusion (PHP) with melphalan using the CHEMOSAT Hepatic Delivery System in patients with liver-dominant metastatic uveal melanoma (mUM).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ESMO Congress 2026 Presentation Details

Company Sponsored Trial-in-Progress Poster Presentation
Title: DELUMA: An Open-Label, Randomized Phase II Study of Melphalan/HDS Induction Followed by Standard Therapy vs Standard Therapy Alone in Patients with Liver-Dominant Metastatic Breast Cancer
Abstract Number: 58TiP
Presenter: Heather McArthur, MD, MPH; UT Southwestern Medical Center, Global Principal Investigator
Date/Time: Saturday, October 24, 2026, 12:00 CEST
Location: Poster Area, Hall 5, IFEMA Madrid

"Meet the Investigators" Session
Date/Time: Saturday, October 24, 2026, 16:30–17:00 CEST
Location: Valencia Auditorium

Del-Liver Phase 2 trial in metastatic colorectal cancer – update presented by Global Principal Investigator Marwan Fakih, MD, City of Hope
Deluma Phase 2 trial in metastatic breast cancer – update presented by Global Principal Investigator Heather McArthur, MD, MPH, UT Southwestern Medical Center
The session will conclude with an open Q&A discussion.

Poster Presentation – Independent Investigator
Title: Liver-metastatic uveal melanoma comparison: melphalan hepatic delivery (PHP) + ipilimumab/nivolumab versus tebentafusp
Abstract Number: 2135P
Presenter: Cato Boreel, Dutch Institute for Clinical Auditing (Dutch Melanoma Treatment Registry)
Session Type: Poster
Date/Time: Saturday, October 24, 2026, 12:00 CEST
Location: Poster Area, Hall 5, IFEMA Madrid
Summary: Compares regional treatment (melphalan hepatic delivery/PHP) plus ipilimumab/nivolumab with systemic tebentafusp in patients with liver-metastatic uveal melanoma.

Independent Analysis of CHEMOSAT PHP in Liver-Dominant Metastatic Uveal Melanoma

Independent investigators from St Vincent’s University Hospital in Dublin, Ireland published a retrospective analysis of patients with liver-dominant mUM who were referred to University Hospital Southampton for chemosaturation with percutaneous hepatic perfusion (CS-PHP) between 2019 and 2026. The abstract, "Outcomes and safety of chemosaturation with percutaneous hepatic perfusion (CS-PHP) in liver-dominant metastatic uveal melanoma: Impact of molecular profiling on survival" (Abstract 119P), appears in ESMO (Free ESMO Whitepaper) Open, Volume 11, Supplement 7 (September 2026), and is available here.

Key findings (retrospective cohort; N=12):

Patients received a median of 3 CS-PHP cycles (median age 58 years).
Objective response rate (ORR) was 66.7% and disease control rate (DCR) was 75% per RECIST 1.1.
Median hepatic progression-free survival was 18.4 months and median overall survival was 28 months.
Serious adverse events were reported in 3 patients, including pulmonary embolism and one procedural hemorrhage; no treatment-related deaths occurred.
In exploratory analyses, BAP1 loss and monosomy 3 (each identified in 6 of 12 patients) were associated with shorter survival.

(Press release, Delcath Systems, OCT 19, 2026, View Source [SID1234673568])